CHARLOTTESVILLE, VA – Monday, June 15, 2015 – Diffusion Pharmaceuticals LLC, a clinical-stage biotech company developing improved treatments for cancer and other life-threatening unmet medical conditions, today announced that Alan Levin has joined the Company’s Board of Directors and will chair its newly formed Audit Committee.

Diffusion has recently completed a phase 1/2 clinical trial of its lead drug, trans sodium crocetinate (TSC), a novel small molecule designed to enhance the effectiveness of current cancer treatments by safely reducing tissue hypoxia and strengthening the body’s response to radiation and chemotherapy. The trial, which enrolled 59 newly diagnosed primary brain cancer (glioblastoma or GBM) patients in 18 major medical centers around the country, tested the safety and efficacy of TSC as an addition to the current GBM standard of care over the 24 month period ending in April 2015. Diffusion’s staff is currently compiling and analyzing the data and planning its phase 3 TSC development program in preparation for an end-of-phase 2 meeting with the US Food and Drug Administration (FDA) later this summer.

Diffusion Pharmaceuticals CEO David Kalergis said, “We’re gratified to have been able to attract and add such an accomplished pharmaceutical industry veteran as Alan Levin to our Board. His advice will be invaluable as we move the Company forward into our advanced clinical development program.”

Alan served as Executive Vice President & Chief Financial Officer of Endo Health Solutions Inc. (Endo) from June 2009 until September 2013. Prior to joining Endo, Mr. Levin worked with Texas Pacific Group, a leading private equity firm, and one of their start-up investments. Before that, he was Senior Vice President & Chief Financial Officer of Pfizer Inc., where he worked for 20 years in a variety of executive positions of increasing responsibility. Mr. Levin received a bachelor’s degree from Princeton University and a master’s degree from New York University’s Stern School of Business. He is a certified public accountant and a member of the Advisory Board of Auven Therapeutics, a private equity fund, where he chairs the fund’s Audit & Risk Committee. He is also a member of the Board of Directors of Aceto Corp, a NASDAQ-traded company specialized in generics and pharmaceutical intermediate products and the Critical Path Institute, a nonprofit collaboration between the Food and Drug Administration and the pharmaceutical industry, focused on streamlining and accelerating the development and regulatory pathways for innovative medicines.